The Lancet Oncology in conversation with
The Lancet Group 81 episodes Oct 26, 2026
A monthly audio companion to The Lancet Oncology in which the journal's editors talk with authors about their latest research and its implications for health, healthcare and health policy. Episodes cover a broad range of oncology topics, from early-stage breast cancer treatment and mRNA vaccines to access to essential cancer medicines for children and the measurement of ovarian toxicity. Each conversation offers insight into the science behind the studies and what the findings mean for patients and clinical practice.
Episodes
Iberdomide, daratumumab, and dexamethasone in relapsed or refractory multiple myeloma with Professor Lonial
Iberdomide, daratumumab, and dexamethasone as a treatment option for patients with relapsed or refractory multiple myeloma.
Click here the full article:
S1470-2045(26)00450-X
Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler
In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Belfast, UK) to discuss the outcomes and implications of the latest Lancet Oncology Commission on cccelerating equitable c
Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi
Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology.
To read t
5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova
5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer.
Click here to read the full
Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission.
To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce.
To
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).
Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext
Tell us what you thought about this episode
Ali Landman on the European Congress of Radiology 2026
Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026.
To learn more:
European Congress of Radiology: https://www.myesr.org/congress/
The La
Kayleigh Bhangdia on breast cancer GBD study 2023
Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas
Dylan Graetz and Erica Kaye on qualitative research in oncology
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology.
Read the full Reviews:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)006
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.
Click here to read the full article: http
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.
Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission
And comment: Re-establishing human-centred care
Tell us what you thought about this episode
Continue this con
Matthias Preusser on the phase 2 TUXEDO-3 trial
Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.
Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patie
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.
Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.
In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in menin
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer
Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article
Abdalla Awidi on cancer control in the Middle East
Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments.
See th
ASCO 2025 Debrief
Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference.
If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here:
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.
This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of t
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprou
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https:/
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.co
Yannick Romero on the changing landscape of national cancer control plans
Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about thi
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.
Read the full Series:
https://www.thelancet.com/series/cancer-care-in-saarc-co
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.
Read the full Articles here:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.
Read the full Article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Con
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.
Read the Commission:
https://www.thelancet.com/commissions/radiotherapy-thera
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-
Emmy Boerrigter on dose selection of novel anticancer drugs
Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
C
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment
Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelanc
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean
Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.
Read
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thoug
Maria Kyrgiou on innovations in gynaecological cancers and global disparities
In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thel
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers
Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://in
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprou
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma
Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https:/
Neerja Bhatla on a new quadrivalent HPV vaccine
Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dg
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery
Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/the
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma
Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.
Read the full Policy Review:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podc
Wanda Cui on measuring ovarian toxicity
Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on soc
Ticiana Leal on Tumour Treating Fields
Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.b
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA
Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us what you thought about this episode
Continue this c
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma
Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
Tell us wh
Madeline Pe on the SISAQOL initiative
Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00157-2/fulltext?dgcid=buzzsprout
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children
Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.
Read the full article:
https://www.thelancet.com/journals/lano
Mark Lythgoe on UK oncology drug approval after Brexit
Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
http
Janet Brown on the phase 2/3 STAR trial
Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.
Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)
Tell us what you th
Valerie Speirs on biomarkers in male breast cancer
Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.
Read the full article:
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer
Tell us what you thought about this episode
Con
Sameer Bakhshi on sex disparities in childhood cancer in India
Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.
Read the full article:
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.soci
Shankar Siva on radiotherapy for primary renal cell carcinoma
Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.
Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma
Tell us what you thought about this episode
Continue this conversation on social!
Follow us t
Mark Lawler and Richard Sullivan on the European Groundshot
Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://
Samar Alhomoud on challenges for cancer control in the Gulf region
Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.
Read the full article:
Progress and remaining challenges for cancer control in the Gulf Cooperation Council
Tell us what you thought about this episode
Continue this conversation on social!
Follow u
Inge Marie Svane on mRNA vaccines for cancer treatment
Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.
Read the full Review:
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.soci
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.
Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
Tell us what you thought about this episode
Continue this conversation on social!
Ignace Vergote and Maria Kyrgiou on gynaecological cancers
Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers.
Visit the Series hub:
Gynaecological cancers
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com
David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer
David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe.
Read the full article:
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe
Tell us what you thought about this episode
Continue this co
Wilfred Ngwa, Beatrice Wiafe-Addai, and David Kerr on cancer in sub-Saharan Africa
Wilfred Ngwa (Harvard Medical School, Boston, MA, USA; Johns Hopkins University, Baltimore, MD, USA; ICT University, Yaounde, Cameroon), Beatrice Wiafe-Addai (Peace and Love Hospital, Kumasi, Ghana), and David Kerr (University of Oxford, Oxford, UK) discuss the Lancet Oncology Commission on cancer in sub-Saharan Africa.
Tell us what you thought about this episode
Continue this conversation on soci
Georgios Lyratzopoulos on emergency presentation
Georgios Lyratzopoulos (Institute of Epidemiology & Health Care at University College London, London, UK) discusses his population-based study on risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission.
Read the full article:
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital a
Lisa Iezzoni on disabilities and cancer, and Jordan Marchak on mental health problems in young cancer survivors
Lisa Iezzoni (Massachusetts General Hospital, Boston, MA, USA) discusses her Series paper on disabilities and cancer and Jordan Marchak (Children’s Healthcare of Atlanta, Atlanta, GA, USA) discusses her Review on surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors.
Read the full articles:
Cancer detection, diagnosis, and treatment for adults with disa
Rosie Bradley on early-stage breast cancer treatment
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer tr
Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer
Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.
Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stag
Rebecca Fitzgerald on Barrett’s oesophagus surveillance
Rebecca Fitzgerald (University of Cambridge, Cambridge, UK) discusses her Article on the use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance.
Read the full article:
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance
Tell us what you thought about this episode
Continue this conversation on social!
Follow us toda
Elysia Alvarez on adolescent and young adult cancer
Elysia Alvarez (UC Davis Comprehensive Cancer Center, Sacramento, USA) discusses her Article on the analysis of the global burden of adolescent and young adult cancer in 2019.
Read the full article:
The global burden of adolescent and young adult cancer in 2019
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
h
Aju Mathew on cancer care in India
Aju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00468-X/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social
David Pinato on cancer patients who recovered from SARS-CoV-2 infection
David Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection.
Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00573-8/fulltext
Tell us what you thought about this episode
Continue this conv
James Glasbey on the effect of lockdowns on cancer surgery
James Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00493-9/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follo
Manju Sengar and Christopher Booth on essential cancer drugs
Manju Sengar (Tata Memorial Centre, India) and Christopher Booth (Queen’s University Cancer Research Institute, Canada) discuss their Article on the comparison between cancer drugs deemed essential by oncologists and those included in the WHO Essential Medicines List.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00463-0/fulltext
Tell us what you though
Susannah Stanway, Richard Cowan, Danielle Rodin, and Miriam Mutebi on helping with cancer control in LMICs
Susannah Stanway (UK Global Cancer Network), Richard Cowan (Christie NHS Foundation Trust, UK), Danielle Rodin (Princess Margaret Cancer Centre, Canada), and Miriam Mutebi (Aga Khan University Hospital, Kenya) discuss the Global Cancer Control Networks Series on how high-income countries, particularly the UK and Canada, can help with cancer control in low-income and middle-income countries.
Read
Harriet Rumgay on the burden of cancer attributable to alcohol
Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00279-5/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky
Rafael Cardoso and Hermann Brenner on colorectal cancer
Rafael Cardoso and Hermann Brenner (German Cancer Research Center, Heidelberg, Germany) discuss their recent paper on colorectal cancer incidence, mortality, and stage distribution in Europe.
Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00199-6/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at.
Takayuki Yoshino on the DESTINY-CRC01 trial
Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today
Roberto Orecchia on the ELIOT trial
Roberto Orecchia (European Institute of Oncology IRCCS) discusses the ELIOT trial on intraoperative irradiation for early breast cancer.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00080-2/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.co
Hedvig Hricak, Andrew Scott, Rifat Atun, and May Abdel-Wahab on nuclear medicine
Hedvig Hricak (Memorial Sloan Kettering Cancer Center), Andrew Scott (Olivia Newton-John Cancer Research Institute), Rifat Atun (Harvard TH Chan School of Public Health), and May Abdel-Wahab (International Atomic Energy Agency) discuss the latest Lancet Oncology’s Commission on Medical Imaging and Nuclear Medicine.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470
Ariana Znaor on breast and cervical cancer in the former Soviet Union
Ariana Znaor, International Agency for Research on Cancer, discusses her Article on breast and cervical cancers stage distributions in ten newly independent states of the former Soviet Union.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30674-4/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at
Sathira Perera on global cancer surgery
Sathira Perera (University of New South Wales, Australia) discusses his (and colleagues) Articles on the global use of cancer surgery.
Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30675-6/fulltext
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com
Short-course radiotherapy for advanced rectal cancer
Geke Hospers (University Medical Center Groningen, The Netherlands) discusses the RAPIDO trial Article published in The Lancet Oncology.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https:
